B-Raf IN 17

Cat. No.:	HY-158027
Molecular Formula:	$C_{22}H_{14}BrN_5O_2$
Molecular Weight:	460.28
Target:	Raf; VEGFR; FGFR
Pathway:	MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of $BRAF_{WT}$, VEGFR-2, and FGFR-1 in A375 cell line, with IC_{50} values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer[1].

In Vivo

B-Raf IN 17 (10-20mg/kg, p.o., three time pre week for 21 days) inhibits tumor growth in C57BL/6 mice bearing B16F10 cells [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice bearing B16F10 cells
Dosage:	10-20mg/kg
Administration:	p.o., three time pre week for 21 days
Result:	Prolonged the overall survival time. Reduced angiogenesis markers, mRNA expression levels of VEGFR-2 and FGFR-1, and production of growth factors. Downregulated Notch1 protein expression and decreased TGF-β1 production.

REFERENCES

[1]. Allam RM, et al. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. Bioorg Chem. 2024 Feb 26;146:107243.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA